Glycoprotein Hormones Patents (Class 530/397)
-
Publication number: 20030171559Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.Type: ApplicationFiled: December 20, 2001Publication date: September 11, 2003Applicant: Amgen Inc.Inventor: Timothy David Osslund
-
Patent number: 6600019Abstract: The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: January 4, 2001Date of Patent: July 29, 2003Assignee: CuraGen CorporationInventors: Sudhirdas K. Prayaga, Kumud Majumder, Bruce Taillon, Steven Kurt Spaderna, Kimberly Spytek, John MacDougall
-
Patent number: 6586398Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).Type: GrantFiled: April 7, 2000Date of Patent: July 1, 2003Assignee: Amgen, Inc.Inventors: Olaf Kinstler, Colin Gegg, Aimee Freeman, Thomas Boone
-
Publication number: 20030120045Abstract: Conjugates of erythropoietin with poly(ethylene glycol) comprise an erythropoietin glycoprotein having at least one free amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to “n” poly(ethylene glycol) groups of the formula —CO—(CH2)x(OCH2CH2)m—OR with the carbonyl of each poly(ethylene glycol) group forming an amide bond with one of said amino groups; wherein R is lower alkyl; x is 2 or 3; m is about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons.Type: ApplicationFiled: November 14, 2002Publication date: June 26, 2003Inventor: Pascal Sebastian Bailon
-
Patent number: 6583272Abstract: Conjugates of erythropoietin with poly(ethylene glycol) comprise an erythropoietin glycoprotein having at least one free amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; the glycoprotein being covalently linked to “n” poly(ethylene glycol) groups of the formula —CO—(CH2)x(OCH2CH2)m—OR with the carbonyl of each poly(ethylene glycol) group forming an amide bond with one of said amino groups; wherein R is lower alkyl; x is 2 or 3; m is about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons.Type: GrantFiled: June 27, 2000Date of Patent: June 24, 2003Assignee: Hoffmann-La Roche Inc.Inventor: Pascal Sebastian Bailon
-
Publication number: 20030104988Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.Type: ApplicationFiled: June 26, 2002Publication date: June 5, 2003Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Publication number: 20030100492Abstract: A molecule is provided capable of promoting high affinity binding of a fibroblast growth factor (FGF) to a FGF receptor (FGFR), said molecule being selected from: (i) a recombinant chimeric fusion molecule comprising the extracellular domain of a syndecan or a fragment thereof fused to a tag suitable for proteoglycan purification, said fusion molecule being post-translationally glycosylated to carry at least one chain of a heparan sulfate having at least one highly sulfated domain; (ii) a DNA sequence encoding a chimeric fusion molecule comprising the extracellular domain of a syndecan or a fragment thereof fused to a tag suitable for proteoglycan purification; and (iii) a sugar molecule from a syndecan carrying at least one chain of a heparan sulfate having at least one highly sulfated domain. The compounds may be used for induction of angiogenesis, bone fracture healing, enhancement of wound healing, promotion of tissue regeneration and treatment of ischemic heart diseases and peripheral vascular diseases.Type: ApplicationFiled: September 24, 2002Publication date: May 29, 2003Inventor: Avner Yayon
-
Patent number: 6555660Abstract: The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.Type: GrantFiled: July 11, 2001Date of Patent: April 29, 2003Assignee: Maxygen Holdings Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Patent number: 6534634Abstract: The present invention relates to diagnosis aids and processes for detecting pregnancy in ruminants based on the relaxin-like factor detectable in ruminants. Antibodies against the relaxin-like factor from ruminants as well as against fragments and/or active derivatives of the same with the same immunogenicity are also provided.Type: GrantFiled: May 20, 1999Date of Patent: March 18, 2003Assignee: IHF Institut fur Hormon- und Fortpflanzungsforschung GmbHInventor: Richard Ivell
-
Patent number: 6531122Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: GrantFiled: August 25, 2000Date of Patent: March 11, 2003Assignee: MaxyGen ApSInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Paul Baad Rasmussen
-
Publication number: 20030036181Abstract: Glycosylated polypeptides comprising the primary structure NH2—X—Pp—COOH, wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH2-Px—X—Py-COOH, wherein Px is an N-terminal part of a polypeptide Pp of interest, Py is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site are provided. The glycosylated polypeptides possess improved properties as compared to the polypeptide of interest.Type: ApplicationFiled: June 29, 2001Publication date: February 20, 2003Inventors: Jens Sigurd Okkels, Anne Dam Jensen, Bart van den Hazel
-
Patent number: 6486303Abstract: The present invention relates to a method for preparing heterodimeric analogs of cysteine knot proteins. More specifically, the invention relates to a method for forming a subunit combination of a cysteine knot protein having an &agr;-subunit and a &bgr;-subunit to prepare a heterodimeric protein analog which comprises the steps of (a) attaching a dimerization domain to the amino termini of both an &agr;-subunit and &bgr;-subunit of a cysteine knot protein; and (b) dimerizing the &agr;-subunit and &bgr;-subunit to form a heterodimeric protein analog.Type: GrantFiled: April 14, 1998Date of Patent: November 26, 2002Assignee: University of Medicine & Dentistry of New JerseyInventor: William R. Moyle
-
Publication number: 20020169292Abstract: Compositions and methods based on mutant Cystine Knot Growth Factors (CKGFs) comprising amino acid substitutions relative to the wild type hormone/growth factor. Mutated glycoprotein hormones, including thyroid stimulating hormone (TSH) and chorionic gonadotropin (CG) are disclosed as exemplary mutant CKGFs. Mutant TSH heterodimers and hCH heterodimers possessed modified bioactivities, including superagonist activity. Accordingly, the present invention provides methods for using mutant CKGFs, CKGF analogs, fragments, and derivatives thereof for treating or preventing diseases. Pharmaceutical and diagnostic compositions, methods of using mutant TSH heterodimers and TSH analogs with utility for treatment and prevention of metabolic and reproductive diseases are also provided.Type: ApplicationFiled: March 20, 2001Publication date: November 14, 2002Inventors: Bruce D. Weintraub, Mariusz W. Szkudlinski
-
Publication number: 20020155998Abstract: Erythropoietin analog-human serum albumin (EPOa-hSA) fusion protein and methods of making and using the fusion protein.Type: ApplicationFiled: February 20, 2002Publication date: October 24, 2002Applicant: Genzyme Transgenics Corporation, a Massachusetts corporationInventors: Michael Young, Harry Meade, Ian Krane
-
Patent number: 6465259Abstract: A method for quantitatively and/or qualitatively assaying an analyte in a sample, wherein the analyte is a receptor binding compound, has low detection limits equivalent to those of radioreceptor assays. The method comprises the steps of a) contacting the sample with material comprising a receptor for the analyte in order for receptor-analyte binding to occur and b) further contacting the sample with a detectable ligand for the receptor in order for receptor-ligand binding to occur, followed by c) separating the resulting receptor bound and free fractions, d) subjecting the receptor bound fraction to dissociating conditions releasing the ligand from the receptor and e) assaying for the dissociated ligand in a manner known per se for the detection of the detectable ligand.Type: GrantFiled: May 6, 1999Date of Patent: October 15, 2002Assignee: Merska B.V.Inventors: Maria Johanna Janssen, Kornelis Ensing, Rokus Arie De Zeeuw
-
Publication number: 20020127652Abstract: Heterodimeric polypeptide conjugates exhibiting FSH activity, comprising a dimeric polypeptide comprising an FSH-&agr; subunit and an FSH-&bgr; subunit, wherein at least one of the FSH-&agr; and FSH-&bgr; subunits differs from the corresponding wildtype subunit in that at least one amino acid residue acid residue comprising an attachment group for a non-polypeptide moiety has been introduced or removed, and having at least one non-polypeptide moiety bound to an attachment group of at least one of said subunits are provided. Preferably, at least one attachment group, e.g., an N- or O-glycosylation site or an attachment site for a polymer molecule such as polyethylene glycol, has been introduced, e.g., at an N-terminal. The polypeptide conjugates exhibit improved properties, in particular an increased half-life, compared to human FSH.Type: ApplicationFiled: February 9, 2001Publication date: September 12, 2002Inventors: Hans Thalsgard Schambye, Kim Vilbour Andersen, Bart van den Hazel, Jesper Christiansen, Claus Bekker Jeppesen
-
Patent number: 6444639Abstract: The use of hCG, hCG &bgr;-subunit, as well as fragments and active derivatives thereof, or hCG &bgr;-core in the preparation of a medicament for the prophylaxis and/or the treatment of pathologies requiring inhibition of the matrix metalloprotease (MMP) enzymatic activity.Type: GrantFiled: November 24, 1999Date of Patent: September 3, 2002Assignee: Applied Research Systems ARS Holding N.V.Inventors: Adriana Albini, Giorgia Orengo
-
Publication number: 20020110909Abstract: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the &agr;-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The inventions is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the &bgr;-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone.Type: ApplicationFiled: January 25, 2002Publication date: August 15, 2002Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub, Mathis Grossmann
-
Patent number: 6414123Abstract: The present invention provides a method for purifying follicle stimulating hormone (FSH) from biological samples, for example, from human pituitary glands or human postmenopausal urine, wherein the FSH is contaminated with other proteins, by use of dye-ligand affinity chromatography (DAC). Depending on the starting material used and the initial purity of FSH in the starting material, additional purification steps may be employed. These steps preferably involve the use of hydrophobic interaction chromatography. This process may be used to generate affinity pure FSH suitable for therapeutic applications. The methods of the invention provide high purity FSH with high overall yield. A further advantage is the ability to easily regenerate the chromatography media for re-use, thus providing added economy to the purification process.Type: GrantFiled: November 16, 1999Date of Patent: July 2, 2002Assignee: Vitro Diagnostics, Inc.Inventors: James R. Musick, Erik Van Horn
-
Patent number: 6395883Abstract: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.Type: GrantFiled: March 13, 1995Date of Patent: May 28, 2002Assignee: Curis, Inc.Inventors: William K. Jones, Ronald F. Tucker, David C. Rueger, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath
-
Patent number: 6361992Abstract: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the &agr;-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the &bgr;-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone.Type: GrantFiled: November 3, 1998Date of Patent: March 26, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Mariusz W. Szkudlinski, Bruce D. Weintraub, Mathis Grossmann
-
Publication number: 20020025933Abstract: The present invention relates to derivatives of hGLP-2 and analogues and/or fragments thereof having a lipophilic substituent have interesting pharmacological properties, in particular they have a more protracted profile of action than the parent peptides.Type: ApplicationFiled: July 18, 2001Publication date: February 28, 2002Inventors: Liselotte Bjerre Knudsen, Per Olaf Huusfeldt, Per Franklin Nielsen, Niels C. Kaarsholm, Helle Birk Olsen, Lars Thim, Soren Erik Bjorn
-
Patent number: 6348568Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.Type: GrantFiled: May 20, 1999Date of Patent: February 19, 2002Assignee: Trimeris, Inc.Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
-
Publication number: 20020015981Abstract: Novel &bgr;10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing &bgr;10 polypeptides and heterodimeric forms thereof, specifically &agr;2/&bgr;10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with &bgr;10 polypeptides and &agr;2/&bgr;10 heterodimers or their respective binding agents.Type: ApplicationFiled: March 27, 2001Publication date: February 7, 2002Inventors: Christopher J.R. Paszty, Jin Cao, Dimitry M. Danilenko, Jianhua Gong, David C. Hill
-
Patent number: 6333164Abstract: There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.Type: GrantFiled: March 4, 1999Date of Patent: December 25, 2001Assignee: Takara Shuzo Co., Ltd.Inventors: Kazutoh Takesako, Shigetoshi Mizutani, Masahiro Endo, Ikunoshin Kato
-
Patent number: 6333306Abstract: The present invention is directed to a pharmaceutical combination preparation comprising 2,000-7,000 U of recombinant human erythropoietin (EPO) and 5-20 mg of an Fe(III) complex, wherein the rhEPO and the Fe(III) complex may be present in separate administration forms or in an integrated administration form. The pharmaceutical preparation is used in the treatment of anemias or hemodialysis patients.Type: GrantFiled: March 16, 1998Date of Patent: December 25, 2001Assignee: Roche Diagnostics GmbHInventor: Paul Lehmann
-
Publication number: 20010041792Abstract: Disclosed herein are novel methods of obtaining osteogenic and other growth factor compositions from alternative nonbone sources such as tissue or bone marrow, and methods of using the same. Also disclosed are implants infused with growth factors obtained from the methods disclosed herein.Type: ApplicationFiled: February 2, 2001Publication date: November 15, 2001Inventors: Russell S. Donda, John F. Wironen
-
Patent number: 6284872Abstract: Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.Type: GrantFiled: February 28, 1997Date of Patent: September 4, 2001Assignees: Genetics Institute, Inc., President and Fellows of Harvard CollegeInventors: Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
-
Patent number: 6274550Abstract: A proteoglycan (“azaftig”) with a molecular weight of approximately 24,000 Dalton has been isolated and partially characterized from the urine of cachectic cancer and non-cancer patients. Azaftig has been shown to bind to receptors on fat cell membranes, and to cause lipolysis. Azaftig does not bind to muscle cell membranes, or cause proteolysis in muscle tissue. Azaftig detection in urine or other body fluids will allow early identification of patients in which weight loss may become a problem. Azaftig may also aid fat loss in humans in which obesity is a threat to health.Type: GrantFiled: June 28, 1999Date of Patent: August 14, 2001Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Chandan Prasad, Julio E. Figueroa, II, Parakat Vijayagopal
-
Publication number: 20010007757Abstract: The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.Type: ApplicationFiled: December 8, 2000Publication date: July 12, 2001Inventors: Irving Boime, Martin M. Matzuk, Jeffrey L. Keene
-
Patent number: 6242580Abstract: Single-chain forms of the glycoprotein hormone quartet, at least some members of which are found in most vertebrates, are disclosed. The &agr; and &bgr; subunits of the wild-type heterodimers or their variants or their fragments are covalently linked, optionally through a linker moiety. Some of the single-chain forms are agonists and others antagonists of the glycoprotein hormone activity.Type: GrantFiled: March 31, 1999Date of Patent: June 5, 2001Assignee: Washington UniversityInventors: Irving Boime, William R. Moyle
-
Patent number: 6232291Abstract: The invention relates to Cytostatin III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: GrantFiled: May 10, 1999Date of Patent: May 15, 2001Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Reiner Gentz, Patrick J. Dillon
-
Patent number: 6210736Abstract: Transgenically produced prolactin and methods of making and using transgenically produced prolactin are disclosed.Type: GrantFiled: June 15, 1998Date of Patent: April 3, 2001Assignee: Genzyme Transgenics CorporationInventors: Yann Echelard, Brian Wilburn
-
Patent number: 6204359Abstract: An isolated and purified polypeptide having heparin binding properties with the amino acid sequence of SQ ID No: 1 and pharmaceutical compositions for treating skin wounds.Type: GrantFiled: June 10, 1998Date of Patent: March 20, 2001Assignee: Innogenetics N.V.Inventors: Bernard Delaey, Jos Raymackers, Hugo Van Heuverswyn
-
Patent number: 6180779Abstract: O-glycan is released from a glycoconjugate with a substantially anhydrous hydrazine reagent, the glycoconjugate being substantially salt-free and substantially anhydrous. Released O-glycan is recovered in substantially unreduced and intact form using a chromatographic material.Type: GrantFiled: March 12, 1993Date of Patent: January 30, 2001Assignee: Oxford GlycoSystems LimitedInventors: Rajesh Bhikhu Parekh, Anthony Hugh Merry, James Bruce
-
Patent number: 6171822Abstract: The present invention relates to polynucleotide and polypeptide molecules for stanniocalcin-2, a novel member of the stanniocalcin family. The polypeptides, and polynucleotides encoding them, modulate electrolyte homeostasis. The present invention also includes antibodies to the stanniocalcin-2 polypeptides.Type: GrantFiled: October 11, 1999Date of Patent: January 9, 2001Assignee: ZymoGenetics, Inc.Inventors: Rolf E. Kuestner, Darrell C. Conklin, Si Lok, Michele Buddle, William Downey
-
Patent number: 6153592Abstract: Proteins or peptidic substances, which may be prepared from naturally occurring proteins, enhance the bioavailability of proteolytically-labile therapeutic agents which, in the absence of the protein or peptidic substance would suffer enzymatic inactivation upon administration.Type: GrantFiled: September 8, 1994Date of Patent: November 28, 2000Assignee: Port Systems, LLCInventors: Gordon L. Amidon, Glen D. Leesman, Patrick J. Sinko
-
Patent number: 6150326Abstract: Trophoblastic .beta.-I-glycoprotein (TBG) is used as a means for treating autoimmune diseases showing suppressors immunodeficit.A method of treating of autoimmune diseases comprises the administration of an immune correcting preparation, said preparation being trophoblastic .beta.-I-glycoprotein (TBG), indications with respect to said preparation being determined by testing TBG sensitivity of mononuclear cells (MNCs).Type: GrantFiled: November 15, 1996Date of Patent: November 21, 2000Assignees: Leonid Yazonovich Kacharava, Ivan Nikolaevich GolovistikovInventors: Ivan Nikolaevich Golovistikov, Leonid Yazonovich Kacharava, Jury Semyonovich Tatarinov, Khallar Abdumuslimovich Alikhanov
-
Patent number: 6150331Abstract: Provided is an aqueous pharmaceutical composition comprising human growth hormone wherein said human growth hormone is dissolved in a benzalkonium chloride-containing, slightly to weakly acidic solution buffered, most preferably, with maleate. The composition is sufficiently stable to be supplied in liquid state and can be prepared as a less painful composition.Type: GrantFiled: December 18, 1998Date of Patent: November 21, 2000Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Masafumi Tatsumi, Katsura Inoue, Junichi Kajihara
-
Patent number: 6124257Abstract: Compositions and methods of treating disease and injuries wherein by sequentially or co-administering pulmonarily a polypeptide effective for the treatment of the injury or disease and a protease inhibitor capable of binding with elastase or cathepsin G.Type: GrantFiled: November 30, 1998Date of Patent: September 26, 2000Inventors: John Lezdey, Allan Wachter
-
Patent number: 6107272Abstract: The invention relates to novel modified polypeptides, with or without variations in noncoding regions, with altered biological activity. The invention discloses methods of preparing the modified polypeptides and methods of use.Type: GrantFiled: May 18, 1999Date of Patent: August 22, 2000Assignee: Beth Israel Deaconess Medical CenterInventor: Arthur J. Sytkowski
-
Patent number: 6103501Abstract: Single-chain agonists and/or antagonists of the glycoprotein hormones are disclosed. These proteins are of the formula.beta..sup.1 -(linker.sup.1).sub.m -.alpha.-(linker.sup.2).sub.n -.beta..sup.2 (1);or.beta..sup.1 -(linker.sup.1).sub.m -.beta..sup.2 -(linker.sup.2).sub.n -.alpha. (2);or.alpha.-(linker.sup.1).sub.m -.beta..sup.1 -(linker.sup.2).sub.n - .beta..sup.2 (3)wherein each of .beta..sup.1 and .beta..sup.2 has the amino acid sequence of the .beta. subunit of a vertabrate glycoprotein hormone or a variant thereof; ".alpha." designates the .alpha. subunit of a vertabrate glycoprotein hormone or a variant thereof; "linker" refers to a covalently linked moiety that spaces the .beta..sup.1 and .beta..sup.2 subunits at distances from the .alpha. subunit and from each other effective to retain said activity, and each of m and n is independently 0 or 1.Type: GrantFiled: November 17, 1997Date of Patent: August 15, 2000Assignee: Washington UniversityInventors: Irving Boime, David Ben Menahem
-
Patent number: 6075007Abstract: Described are modified Noggin muteins, compositions comprising the muteins, and DNA or RNA sequences comprising coding (sense) or antisense sequences for the muteins.Type: GrantFiled: July 17, 1997Date of Patent: June 13, 2000Assignees: Regeneron Pharmaceuticals, Inc., Regents of the Univ. of CaliforniaInventors: Aris Economides, Neil E. Stahl, Richard M. Harland
-
Patent number: 6051686Abstract: Synthetic polypeptide analogs of parathyroid hormone PTH, parathyroid hormone related peptide PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, in which amino acid residues (22-31) form an amphipathic .alpha.-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:Haa(Laa Laa Haa Haa).sub.2 Laaand their pharmaceutically acceptable salts are useful for the prophylaxis and treatment of ostoporosis in mammals. Processes for the production of the polypeptides via solid phase and recombinant methods are provided.Type: GrantFiled: May 23, 1995Date of Patent: April 18, 2000Assignee: Syntex (U.S.A.) Inc.Inventors: John L. Krstenansky, John J. Nestor, Jr., Teresa H. Ho, Brian H. Vickery, Chinh T. Bach
-
Patent number: 6046033Abstract: A protein is provided derived from human fibroblast having an N-terminal amino acid sequence represented by SEQ ID NOS: 1 and 2, having a molecular weight of approximately 15kD under reducing and non-reducing conditions by (dosium dodecyl sulfate-polyacrylamide gel electrophoresis), and having an activity to stimulate growth of osteoblast. The protein is produced by gene engineering procedures, contains the amino acid sequence represented by SEQ ID NO: 9 and has osteoblast growth activity. Also provided is a method for preparing the protein by culturing human fibroblast and treating the conditioned medium for purification. The protein is utilized for the treatment of diseases characterized by decreased bone mass such as osteoporosis or is utilized as an antigen for immunological diagnosis of diseases.Type: GrantFiled: February 26, 1996Date of Patent: April 4, 2000Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Masaaki Goto, Eisuke Tsuda, Kazuki Yano, Fumie Kobayashi, Kyoji Yamaguchi, Naohiro Washida, Masatsugu Ueda, Tomonori Morinaga, Toshiko Satake, Kanji Higashio
-
Patent number: 6040187Abstract: The method for determining a suppressor component of human immune status comprises collecting peripheral blood, obtaining a suspension of mononuclear cells (MNCs), dividing said suspension into two equal portions, cultivating MNCs in the first portion without a suppressor activator, cultivating MNCs in the second portion with said suppressor activator (TBG), washing MNCs out of culture medium, blocking the proliferation, adding newly isolated MNCs from a normal donor, which MNCs have been stimulated with phytohemagglutinin, into each of MNC portions in equal proportions to obtain test cultures, cultivating said test cultures, further evaluating the proliferation in said test cultures and determining the suppression value on the basis of the ratios of proliferation levels in test cultures.Type: GrantFiled: January 21, 1997Date of Patent: March 21, 2000Assignees: Ivan Nikolaevich Golovistikov, Leonid Yazonovich KacharavaInventors: Ivan Nikolaevich Golovistikov, Leonid Yazonovich Kacharava, Khallar Abdumuslimovich Alikhanov
-
Patent number: 6033903Abstract: The extracellular domain, or fragment thereof, of a gonadotropin glycoprotein hormone receptor is expressed and secreted in a soluble and functionally hormone-binding form. A recombinant baculovirus transfer vector is constructed to include a gene segment encoding the extracellular domain, or fragment thereof, of the glycoprotein hormone receptor joined in frame with a gene segment encoding a baculovirus signal peptide and operably linked to a baculovirus promoter. Recombinant baculovirus generated by transfection or co-transfection of insect cells are then used to infect insect host cells for the expression and secretion of soluble receptor.Type: GrantFiled: June 2, 1995Date of Patent: March 7, 2000Assignee: Applied Research Systems, Ars Holding N.V.Inventors: William P. Sisk, Shirley Vui Yen Cheng, David Rogers Buckler, Holly Lynn Prentice
-
Patent number: 6028169Abstract: Human chemokine .beta.-6 agonist and antagonist polypeptides and DNA encoding such polypeptides and procedure for producing such polypeptides by recombinant technique are disclosed. The chemokine .beta.-6 antagonists of the present invention may be employed to treat rheumatoid arthritis, lung inflammation, allergy, asmtha, infectious diseases and to prevent inflammation and atherosclerosis. The chemokine .beta.-6 agonists may be employed to myeloprotect patients undergoing chemotherapy.Type: GrantFiled: December 19, 1997Date of Patent: February 22, 2000Assignee: Human Genome Sciences, Inc.Inventors: Brent L. Kreider, Steven M. Ruben, Henrik S. Olsen
-
Patent number: 6028177Abstract: Single-chain forms of the glycoprotein hormone quartet, at least some members of which are found in most vertebrates, are disclosed. In these single-chain forms, the .alpha. and .beta. subunits of the wild-type heterodimers or their variants are covalently linked, optionally through a linker moiety. A drug may further be included within the linker moiety to be targeted to receptors for these hormones. Some of the single-chain forms are agonists and others antagonists of the glycoprotein hormone activity. Kits comprising antibodies to these proteins can be used in immunodetection methods.Type: GrantFiled: July 11, 1997Date of Patent: February 22, 2000Assignee: Washington UniversityInventor: Irving Boime
-
Patent number: 6022858Abstract: A pharmaceutical formulation comprising a growth hormone pretreated with zinc and optionally lysine or calcium ions shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.Type: GrantFiled: July 23, 1998Date of Patent: February 8, 2000Assignee: Novo Nordisk A/SInventors: Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim, Christensen Thorkild, Per Balschmidt